vs
Side-by-side financial comparison of UroGen Pharma Ltd. (URGN) and Americas Gold & Silver Corp (USAS). Click either name above to swap in a different company.
UroGen Pharma Ltd. is the larger business by last-quarter revenue ($37.8M vs $19.1M, roughly 2.0× Americas Gold & Silver Corp). On growth, UroGen Pharma Ltd. posted the faster year-over-year revenue change (54.0% vs -28.0%). UroGen Pharma Ltd. produced more free cash flow last quarter ($-38.3M vs $-41.3M).
UroGen Pharma Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urological diseases and specialty cancers. Its core offerings target unmet medical needs for conditions including non-muscle invasive bladder cancer, with primary operations and sales markets across North America and Europe.
Pan American Silver Corporation is a mining company based in Canada with operations in Latin America. The company has mines and other projects in Mexico, Peru, Bolivia, and Argentina.
URGN vs USAS — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $37.8M | $19.1M |
| Net Profit | — | $-15.7M |
| Gross Margin | 91.3% | 34.2% |
| Operating Margin | -50.5% | — |
| Net Margin | — | -82.3% |
| Revenue YoY | 54.0% | -28.0% |
| Net Profit YoY | — | 2.8% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $37.8M | — | ||
| Q3 25 | $27.5M | $19.1M | ||
| Q2 25 | $24.2M | — | ||
| Q1 25 | $20.3M | — | ||
| Q4 24 | $24.6M | — | ||
| Q3 24 | $25.2M | $26.5M | ||
| Q2 24 | $21.8M | — | ||
| Q1 24 | $18.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | $-33.3M | $-15.7M | ||
| Q2 25 | $-49.9M | — | ||
| Q1 25 | $-43.8M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-23.7M | $-16.2M | ||
| Q2 24 | $-33.4M | — | ||
| Q1 24 | $-32.3M | — |
| Q4 25 | 91.3% | — | ||
| Q3 25 | 88.1% | 34.2% | ||
| Q2 25 | 85.3% | — | ||
| Q1 25 | 88.5% | — | ||
| Q4 24 | 89.9% | — | ||
| Q3 24 | 90.3% | 23.6% | ||
| Q2 24 | 89.8% | — | ||
| Q1 24 | 90.8% | — |
| Q4 25 | -50.5% | — | ||
| Q3 25 | -99.7% | — | ||
| Q2 25 | -171.2% | — | ||
| Q1 25 | -182.3% | — | ||
| Q4 24 | -112.6% | — | ||
| Q3 24 | -69.6% | — | ||
| Q2 24 | -118.3% | — | ||
| Q1 24 | -137.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | -121.3% | -82.3% | ||
| Q2 25 | -206.2% | — | ||
| Q1 25 | -216.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -93.9% | -60.9% | ||
| Q2 24 | -152.9% | — | ||
| Q1 24 | -171.9% | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $160.1M | $39.1M |
| Total DebtLower is stronger | $125.0M | — |
| Stockholders' EquityBook value | $-105.5M | $50.2M |
| Total Assets | $200.5M | $234.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $160.1M | — | ||
| Q3 25 | $153.8M | $39.1M | ||
| Q2 25 | $176.0M | — | ||
| Q1 25 | $216.1M | — | ||
| Q4 24 | $282.7M | — | ||
| Q3 24 | $278.9M | — | ||
| Q2 24 | $272.3M | — | ||
| Q1 24 | $183.2M | — |
| Q4 25 | $125.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-105.5M | — | ||
| Q3 25 | $-115.4M | $50.2M | ||
| Q2 25 | $-93.4M | — | ||
| Q1 25 | $-46.5M | — | ||
| Q4 24 | $-8.8M | — | ||
| Q3 24 | $25.5M | $53.1M | ||
| Q2 24 | $30.3M | — | ||
| Q1 24 | $-40.1M | — |
| Q4 25 | $200.5M | — | ||
| Q3 25 | $185.0M | $234.7M | ||
| Q2 25 | $208.7M | — | ||
| Q1 25 | $247.6M | — | ||
| Q4 24 | $285.7M | — | ||
| Q3 24 | $301.9M | — | ||
| Q2 24 | $281.8M | — | ||
| Q1 24 | $200.6M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-38.3M | $-12.5M |
| Free Cash FlowOCF − Capex | $-38.3M | $-41.3M |
| FCF MarginFCF / Revenue | -101.3% | -216.5% |
| Capex IntensityCapex / Revenue | 0.0% | 150.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-162.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-38.3M | — | ||
| Q3 25 | $-42.3M | $-12.5M | ||
| Q2 25 | $-39.8M | — | ||
| Q1 25 | $-42.0M | — | ||
| Q4 24 | $-13.6M | — | ||
| Q3 24 | $-27.7M | $2.4M | ||
| Q2 24 | $-23.7M | — | ||
| Q1 24 | $-31.7M | — |
| Q4 25 | $-38.3M | — | ||
| Q3 25 | $-42.4M | $-41.3M | ||
| Q2 25 | $-40.0M | — | ||
| Q1 25 | $-42.1M | — | ||
| Q4 24 | $-13.7M | — | ||
| Q3 24 | $-27.8M | $-11.2M | ||
| Q2 24 | $-23.8M | — | ||
| Q1 24 | — | — |
| Q4 25 | -101.3% | — | ||
| Q3 25 | -154.1% | -216.5% | ||
| Q2 25 | -165.0% | — | ||
| Q1 25 | -207.7% | — | ||
| Q4 24 | -55.9% | — | ||
| Q3 24 | -110.1% | -42.2% | ||
| Q2 24 | -109.1% | — | ||
| Q1 24 | — | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.3% | 150.8% | ||
| Q2 25 | 0.6% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.5% | — | ||
| Q3 24 | 0.4% | 51.2% | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.0% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
URGN
| Jelmyto | $23.8M | 63% |
| Other | $14.0M | 37% |
USAS
Segment breakdown not available.
